COR Stock Overview
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Cencora, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$227.64 |
| 52 Week High | US$253.27 |
| 52 Week Low | US$199.75 |
| Beta | 0.46 |
| 1 Month Change | -5.24% |
| 3 Month Change | -0.37% |
| 1 Year Change | 12.76% |
| 3 Year Change | 78.39% |
| 5 Year Change | 166.50% |
| Change since IPO | 7,608.44% |
Recent News & Updates
Recent updates
Cencora's (NYSE:COR) Soft Earnings Are Actually Better Than They Appear
Dec 05
Cencora (NYSE:COR) Is Increasing Its Dividend To $0.55
Nov 09Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price
Oct 31Here's Why We Think Cencora (NYSE:COR) Is Well Worth Watching
Oct 10Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly
Sep 18Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating
Sep 18Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings
Jul 16Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning
Jun 30Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?
Jun 28Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly
Jun 09Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?
May 21Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings
Apr 05Cencora Remains Chronically Undervalued, With Material Growth Potential
Mar 25Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 18Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly
Feb 25Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 07Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price
Jan 05Cencora: Continued Economic Value On The Table Across All Investment Horizons
Jan 04Cencora: New Name, Same Old Economic Leverage, Reiterate Buy
Oct 18AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)
Jul 28Shareholder Returns
| COR | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -4.0% | -8.8% | 0.04% |
| 1Y | 12.8% | -9.2% | 27.3% |
Return vs Industry: COR exceeded the US Healthcare industry which returned -9.2% over the past year.
Return vs Market: COR underperformed the US Market which returned 27.3% over the past year.
Price Volatility
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 2.8% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: COR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: COR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1871 | 44,000 | Bob Mauch | www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
| COR fundamental statistics | |
|---|---|
| Market cap | US$44.42b |
| Earnings (TTM) | US$1.51b |
| Revenue (TTM) | US$293.96b |
29.2x
P/E Ratio0.1x
P/S RatioIs COR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COR income statement (TTM) | |
|---|---|
| Revenue | US$293.96b |
| Cost of Revenue | US$284.17b |
| Gross Profit | US$9.79b |
| Other Expenses | US$8.28b |
| Earnings | US$1.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.81 |
| Gross Margin | 3.33% |
| Net Profit Margin | 0.51% |
| Debt/Equity Ratio | 557.8% |
How did COR perform over the long term?
See historical performance and comparison